Omnicell Crushes Q2 EPS Estimates, Raises EBITDA Outlook on Tariff Refund Boost
OMCL sits 45% above its 52-week low of $28.514 on elevated volume (1.9× avg).
Summary
Omnicell delivered a standout Q2, with adjusted EPS of $0.94 nearly doubling the $0.47 consensus. Revenue rose 7% to $312M, aided by a $15M tariff refund that dropped to the bottom line. Management raised full-year non-GAAP EBITDA guidance to $175M-$185M and tightened revenue to $1.225B-$1.245B, while setting initial FY EPS at $2.15-$2.30. The beat and raised outlook signal accelerating demand for its connected device and services portfolio. This follows the earlier Q3 revenue guide of $301M-$307M, adding the full quarterly scorecard and annual profit targets. The stock, trading at 20x forward earnings, may re-rate as analysts digest the magnitude of the beat.
At the time of this announcement, OMCL was trading at $41.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $28.51 to $55.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.